Translation and Notarisation of Dossier Documents

1. Key takeaways

The rules of Myanmar on document language and certification are threefold: (1) the instructions for use and labels must be provided in Myanmar-language and English versions; (2) documents that are not in the Myanmar language must be translated and notarised or legalised; and (3) product names, models and addresses must be completely identical across all documents.

GRZAN note: item (3) is the real risk point of the translation stage. Translation is not a standalone text task but a consistency exercise — the rendering of the same entity name must be uniform across documents, and any spelling or wording difference can trigger a clarification request and lead to months of delay. The language rules can be memorised as: 2 languages, 3 consistency requirements, 1 terminology table.

2. Legal basis

The table below summarises the language, translation and certification requirements that apply to the documents in a Myanmar registration application. Each requirement is checked against the dossier as submitted.

3. Expert insights

Insight 1: the goal of translation is not fluency but verifiability. Reviewers at the Myanmar FDA need to compare the foreign-language documents against the Myanmar-language and English versions, so the uniformity of terminology and proper names takes priority over literary quality. A translation that reads well but renders the same term in two different ways creates exactly the kind of doubt the review is designed to catch. Companies should brief their translators accordingly: the deliverable is a document set in which every controlled term can be traced one to one across languages, not a polished narrative.

Insight 2: the rendering of entity names must be unique. Once the manufacturer name, the address or the product name appears in a document, its rendering should stay the same wherever it reappears. Companies should establish a terminology table and enforce it across the full set of dossier documents. The table is a small artefact with a large effect: it gives translators, reviewers and the authority a single reference, and it converts what would otherwise be a judgement call on every page into a mechanical lookup. Without it, consistency erodes silently with each new document added to the dossier.

Insight 3: notarisation and legalisation are conditional requirements, but they are best completed in advance. The official wording is that the documents must be notarised or legalised when the FDA requires it. In practice, arranging notarisation only after the authority asks for it significantly extends the timeline, because the documents may need to pass through formalities in the country of the manufacturer before they are acceptable. Preparing the notarised versions alongside the originals converts a conditional step into work that is already done, and removes an entire class of timeline risk from the project plan.

Insight 4: the counterfeit consumables problem has raised the authenticity threshold for documents. The focus of the review has shifted from whether documents exist to whether documents are authentic and verifiable. Substantive scrutiny of FSCs and notarised documents has strengthened accordingly. For applicants, this means that unverifiable papers carry real rejection risk, and that the provenance of every certificate matters: who issued it, how it can be checked, and whether the issuing body can be contacted or confirmed. Documents with a clear verification trail survive this scrutiny; documents without one do not.

Insight 5: translation and notarisation belong on the critical path of the project. The time consumed by these two activities is routinely underestimated, and they should be scheduled as separate line items rather than folded into general document preparation. Translation of a full dossier, review of terminology against the table, and notarisation with its external dependencies each take calendar time that cannot be compressed at will. Companies that plan these steps explicitly avoid the situation in which the technical file is ready but the submission must wait for paperwork that could have been finished weeks earlier. Treating these steps as fixed milestones rather than as background tasks running alongside the technical work is the habit that keeps the timetable intact.

4. Practical recommendations

• Establish a terminology table that is uniform across the full dossier. Cover the manufacturer name, the address and the product terminology.
• Review the translations against a standard of verifiability rather than fluency. Give consistency priority over style.
• Complete notarisation and legalisation in advance rather than waiting for a temporary FDA request. This avoids interruptions to the timeline.
• Retain the credentials of the translation provider and the original translations. This facilitates authenticity checks.
• Put translation and notarisation on the project critical path with their own schedule. Budget time for them as separate items.

5. Verification checklist

• □ A terminology table uniform across the full dossier has been established
• □ All translations have been reviewed against the verifiability standard
• □ Notarisation and legalisation have been completed in advance
• □ The credentials of the translation provider and the original translations have been retained
• □ Translation and notarisation have been placed on the critical path
• □ The consistency comparison between the translations and the originals has been completed
• □ The documents have been entered into the registration ledger

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com